![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Active Filter(s):
Details:
Under the terms of the definitive agreement, Jemincare will be responsible for exclusive development and commercialization of the Nafithromycin in the select markets.
Lead Product(s): Nafithromycin
Therapeutic Area: Infections and Infectious Diseases Product Name: WCK 4873
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Jiangxi Jemincare Group Company
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership August 26, 2021